Maibo Pharmaceutical - B(02181.HK)In 2025, sales revenue is approximately 646 million yuan, a year-on-year increase of 150.2%.

NightAirdropper · 2026-03-28T11:39:11+00:00

Maibo Pharmaceutical - Announcement shows that the 2025 annual performance achieved approximately 646 million yuan in sales revenue, an increase of 150.2%, with a profit of 57.1 million yuan, an increase of 144.7%. The company focuses on the development of biopharmaceuticals for cancer and autoimmune diseases, actively expanding into overseas markets, and is expected to achieve even better results in the future.

NightAirdropper

2026-03-28 11:39:11

Abstract generation in progress

Gelonghui March 26 | MIBO Pharmaceutical-B (02181.HK) announced that for the year ended December 31, 2025, the company achieved approximately RMB 646 million in revenue, representing a 150.2% increase year over year. The company achieved profits of RMB 57.10 million, representing an increase of as much as 144.7% compared with the same period last year. In the future, with the rapid progress of industrialization and R&D, and with the company actively expanding overseas markets, the company will achieve even more outstanding results. Earnings per share of RMB 0.01.

The company is a leading biopharmaceutical company in China, focused on the R&D and industrialization of new drugs and biosimilars for the treatment of cancer and autoimmune diseases. The company is committed to bringing high-quality and affordable innovative biologic medicines to the global market through an efficient R&D system and low-cost drug manufacturing capabilities, and to fully leveraging its extensive R&D experience to develop multiple treatment products. As the new drugs the company is developing are gradually approved for market and as sales promotion deepens, the company’s industrialization business has entered a period of rapid growth.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes